Martin Lange
Corporate Officer/Principal bei NOVO NORDISK A/S
Profil
Martin Holst Lange is currently the Director at Pharmacosmos A since 2023 and the Executive Vice President-Development at Novo Nordisk A since 2021.
Previously, he worked as the Director at Novo Nordisk, Inc. from 2006 to 2008 and as the Director at Beta Bionics, Inc. from 2017 to 2020.
Dr. Lange holds multiple doctorate degrees from the University of Copenhagen, conferred in 1997 and 2004.
Aktive Positionen von Martin Lange
| Unternehmen | Position | Beginn |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01.01.2018 |
Pharmacosmos A/S
 Pharmacosmos A/S Pharmaceuticals: MajorHealth Technology Pharmacosmos A/S develops treatments of iron deficiency anemia in humans and animals. Its products include monofer, cosmofer, diafer and uniferon. The company was founded by Dr. Henry M. Christensen in 1965 and is headquartered in Holbæk, Denmark. | Director/Board Member | 18.08.2023 |
Ehemalige bekannte Positionen von Martin Lange
| Unternehmen | Position | Ende |
|---|---|---|
Beta Bionics, Inc.
 Beta Bionics, Inc. Medical SpecialtiesHealth Technology Beta Bionics, Inc. operates a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the autonomous bionic pancreas. The company was founded by Edward R. Damiano in October 21, 2015 and is headquartered in Boston, MA. | Director/Board Member | 20.02.2020 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Director/Board Member | 01.01.2008 |
Ausbildung von Martin Lange
| University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
Beta Bionics, Inc.
Beta Bionics, Inc. Medical SpecialtiesHealth Technology Beta Bionics, Inc. operates a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the autonomous bionic pancreas. The company was founded by Edward R. Damiano in October 21, 2015 and is headquartered in Boston, MA. | Health Technology |
Pharmacosmos A/S
Pharmacosmos A/S Pharmaceuticals: MajorHealth Technology Pharmacosmos A/S develops treatments of iron deficiency anemia in humans and animals. Its products include monofer, cosmofer, diafer and uniferon. The company was founded by Dr. Henry M. Christensen in 1965 and is headquartered in Holbæk, Denmark. | Health Technology |
